147 related articles for article (PubMed ID: 8306248)
1. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
Murray JL; Macey DJ; Kasi LP; Rieger P; Cunningham J; Bhadkamkar V; Zhang HZ; Schlom J; Rosenblum MG; Podoloff DA
Cancer; 1994 Feb; 73(3 Suppl):1057-66. PubMed ID: 8306248
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
3. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
4. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
Meredith RF; Khazaeli MB; Macey DJ; Grizzle WE; Mayo M; Schlom J; Russell CD; LoBuglio AF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3254s-3258s. PubMed ID: 10541372
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
9. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
[TBL] [Abstract][Full Text] [Related]
10. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
11. The biologic window for chimeric L6 radioimmunotherapy.
DeNardo SJ; Mirick GR; Kroger LA; O'Grady LF; Erickson KL; Yuan A; Lamborn KR; Hellstrom I; Hellstrom KE; DeNardo GL
Cancer; 1994 Feb; 73(3 Suppl):1023-32. PubMed ID: 8306244
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
13. Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
Liu T; Meredith RF; Saleh MN; Wheeler RH; Khazaeli MB; Plott WE; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 1997 Apr; 12(2):79-87. PubMed ID: 10851451
[TBL] [Abstract][Full Text] [Related]
14. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49.
Kostakoglu L; Divgi CR; Hilton S; Cordon-Cardo C; Scott AM; Kalaigian H; Finn RD; Schlom J; Larson SM
Cancer Invest; 1994; 12(6):551-8. PubMed ID: 7994589
[TBL] [Abstract][Full Text] [Related]
15. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
[TBL] [Abstract][Full Text] [Related]
16. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
17. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
19. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
Kuzel T; Rosen ST; Zimmer AM; Silverstein EA; Spies S; Saletan SL; Norvitch ME; Birkhofer M; Shochat D; LoBuglio AF
Cancer Biother; 1993; 8(1):3-16. PubMed ID: 7812346
[TBL] [Abstract][Full Text] [Related]
20. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen.
Divgi CR; Scott AM; McDermott K; Fallone PS; Hilton S; Siler K; Carmichael N; Daghighian F; Finn RD; Cohen AM
Nucl Med Biol; 1994 Jan; 21(1):9-15. PubMed ID: 9234259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
